Scammell TE. The Neurobiology, diagnosis and treatment of narcolepsy. Ann Neurol 2003; 53: 154-166
Black JE, Brooks SN, Nishino S. Narcolepsy and syndromes of primary excessive daytime somnolence. Seminars in Neurology 2004; 23 (3): 271- 282
Mignot E. Genetic and familiar aspects of narcolepsy. Neurology 1998; 50 supplement 1): S16-S22
Overreem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: Clinical features, new pathophysiological insights, and future perspectives. J Clin Neurophysiol 2001; 18: 78-105
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39-40
Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-1562
Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Medicine Rev 2001; 5: 349-358
US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of Modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54: 1166-1175
Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-451
Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-376
Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-997
Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002; 11: 91-93
Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-474
